Industry landscapes
The companies, capital and talent shaping healthtech in Boston. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
56 of 576 tracked companies have open roles.
269 of 576 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 579 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 29.3% of disclosed capital, while 53.3% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $421.46M | 31 | 38 |
| 2017 | $989.67M | 39 | 48 |
| 2018 | $880.14M | 28 | 44 |
| 2019 | $451M | 36 | 45 |
| 2020 | $1.1B | 40 | 43 |
| 2021 | $1.17B | 35 | 58 |
| 2022 | $1.04B | 24 | 47 |
| 2023 | $1.27B | 26 | 58 |
| 2024 | $859.54M | 17 | 50 |
| 2025 | $661.87M | 4 | 42 |
Share of all disclosed company funding.
678 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by .
Backed by Palo Santo and Kicker Ventures and others.
Backed by F-Prime Capital and General Catalyst and others.
Backed by .
Backed by .
Backed by .
Backed by Gates.
Participating investors were not recorded in this snapshot.
Backed by General Atlantic and CVS Health and others.
Backed by Philips and Allianz X.
Backed by RA Capital Management and Farallon Capital Management and others.
Participating investors were not recorded in this snapshot.
Backed by Takeda and Allianz X.
Backed by Arch Venture Partners and Lux Capital and others.
Participating investors were not recorded in this snapshot.
Backed by New Enterprise Associates and New Leaf Venture Partners and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 3 reporting entities from 5 eligible matches.
Sum of reporting-entity revenue; not Boston market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 3 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 3 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Beta Bionics ↗1674632 | $100.3m | $-73.2m | -73.0% | — | — |
| Myomo ↗1369290 | $40.9m | $-15.6m | -38.1% | — | — |
| InspireMD ↗1433607 | $9.0m | $-48.8m | -543.3% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Boston companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
9 of the 576 companies on this page carry a measured traffic record (1.6%); these are the largest of those, by monthly visits. The median among them is 158,264 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| SingleCaresinglecare.com | 1,892,214 | 67 | 74.2% |
| CareAcademycareacademy.com | 504,257 | 39 | 90.1% |
| Folx Healthfolxhealth.com | 341,848 | 43 | 78.5% |
| NaviNetnavinet.net | 325,985 | 31 | 3.6% |
| PillPackpillpack.com | 158,264 | 42 | 50.8% |
| Empowerempoweremr.com | 121,194 | 32 | 0% |
| tellescopetellescope.com | 109,932 | 26 | 67.3% |
| Careforthcareforth.com | 82,022 | 35 | 72.9% |
| PatientPalpatientpal.com | 4,965 | 19 | 0% |
Visits and authority are third-party web estimates, not company-reported figures.
68 of these companies (11.8%) publish at least one Android app — 130 apps in all, carrying 18.2M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Kinedu: Baby DevelopmentKinedu | 7.7M | 3.1 | Parenting |
| Ovia Cycle & Pregnancy TrackerOvia Health | 3M | 4.5 | Medical |
| SingleCare - Rx CouponsSingleCare | 3M | 4.5 | Medical |
| Full Code Medical SimulationFull Code Medical | 2M | 3.9 | Medical |
| Ovia Parenting & Baby TrackerOvia Health | 880.2K | 4.6 | Medical |
| MayaMDMaya Md | 408.7K | 4 | Health & Fitness |
| SilverCloudSilverCloud | 201.1K | 3.9 | Health & Fitness |
| WellframeWellframe | 164.5K | 4.5 | Medical |
| Eat Right Now®Eat Right Now | 93.6K | 4.6 | Health & Fitness |
| DietSensor Health & NutritionDietSensor | 91.4K | 3.7 | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 58 | 12.1M | Kinedu: Baby Development 7.7M | |
| Hrtech | 6 | 4.2M | Ovia Cycle & Pregnancy Tracker 3M | |
| Employee Health It | 5 | 4.1M | Ovia Parenting & Baby Tracker 880.2K | |
| Wearable Technology | 8 | 3.9M | Nix Solo 1.8K | |
| Healthcare Booking Platforms | 11 | 3.1M | SingleCare - Rx Coupons 3M | |
| Healthcare It | 66 | 3.1M | Full Code Medical Simulation 2M | |
| Chatbots | 3 | 441.2K | MayaMD 408.7K | |
| Fitness & Wellness Tech | 28 | 177.7K | DietSensor Health & Nutrition 91.4K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 129 of 130 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
39 companies hiring · $9.98B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Beacon Biosignals has raised $97m to advance development of its electroencephalogram (EEG) recording technology in areas including precision medicine and diagnostics.
Flourish Care, a maternal healthcare platform, has raised $5.7 million in seed funding to scale its doula network, the startup shared with MedCity News exclusively.
Precede raised $63.5 million in Series B equity financing and secured a $20 million strategic, non-dilutive credit facility.
BOSTON–(BUSINESS WIRE)–HBox (“HBox” or the “Company”), a leading virtual care platform for specialty practices, announced that it has received a growth investment from Charlesbank’s Technology Opportunities Fund (“TOF”) II.
Mitchell Kapoor’s rating is based on Halozyme’s strategic acquisition of Elektrofi, which brings innovative technology to enhance biologic formulations.
Activated Insights, which is backed by Cressey & Company, has acquired CareAcademy, a Boston-based caregiver education and compliance automation provider. No financial terms were disclosed.
Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures.
Notable AI medtech IPOs in the first half of 2025 have included artificial pancreas maker Beta Bionics, which uses AI algorithms for its decisioning protocols, with a $204m raise in a Nasdaq listing in January.
Patient engagement and payments technology company RevSpring has entered a definitive agreement to purchase Kyruus Health
Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors.
Top 10 categories among 293 recorded events in the 24-month window.
5 companies with recorded IPO activity
IPO · Nasdaq10 reports
Follow-on Offering5 reports
IPO · NASDAQ2 reports
IPO · Nasdaq National Market3 reports
IPO1 reports
20 tracked people moves
Resignation
Appointment Chief Growth Officer
Appointment EVP, chief commercial officer (CCO)
Appointment President and CEO
Appointment Creative Director
Appointment Chief Commercial Officer
Appointment Director of Development Auvergne Rhône-Alpes
Appointment Chief Financial Officer
Products, platforms and features in the recorded window
AI visibility & risk classification
Governance, Risk, and Compliance platform
2 recorded customer wins
Customer: rocheDiagnostics
Customer: Cincinnati Children\'s Hospital Medical CenterMedical imaging
3 companies with reported reductions
338 rolesacquisition by Supernus
25.0% rolescost reduction
10 rolesunpaid salaries
6 recorded events
CE approvalEuropean Commission
approved for post‑partum depressionFDA
rejected for major depressive disorderFDA
CRL issuedFDA
8 tracked suits
unpaid professional services claimCivil · Settled
securities fraudSecurities Fraud · Filed
Reported company results in the recorded window.
Median across 52 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| halozyme therapeutics→Elektrofi ↗ | Completed | 2026-01-28 | Not stated in snapshot |
| activated insights→CareAcademy ↗ | 2025-11-13 | Not stated in snapshot | |
| revspring→Kyruus Health ↗ | Announced | 2025-09-25 | Not stated in snapshot |
| mdxhealth→Exosome Diagnostics ↗ | Completed | 2025-09-15 | $15.0M |
| ascend learning→Laudio ↗ | Announced | 2025-09-11 | Not stated in snapshot |
| beyond bank→Family First ↗ | Announced | 2025-09-04 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1,194 postings in the preceding 12 months. The full 1,709-posting snapshot covers 75 employers.
26 tracked postings mention remote work.
533 postings specify a level.
Top skills across 1,709 tracked postings in the available jobs snapshot.
Median across 138 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Open roles |
|---|---|
| Insulet ↗ | 13 |
| PillPack ↗ | 10 |
| Paragonix Technologies ↗ | 10 |
| Zelis Healthcare ↗ | 10 |
| InspireMD ↗ | 8 |
| Elektrofi ↗ | 8 |
| VideaHealth ↗ | 7 |
| Beacon Biosignals ↗ | 6 |
| Company | Employees |
|---|---|
| Insulet ↗ | 2,600 |
| Zelis Healthcare ↗ | 2,336 |
| Careforth ↗ | 580 |
| kyruus ↗ | 305 |
| Pri-Med ↗ | 201 |
| 3D Diagnostix ↗ | 199 |
| Biofourmis ↗ | 190 |
| aptihealth ↗ | 187 |
461 founders and chief executives across 293 companies.
Ex-Amazon, Quanttus. University of Maryland BSc 1999, Northwestern University MD 2004
World Economic Forum, ex-Boston Consulting, ex-Bain, Harvard University, 2012
Ex-Co-Founder Health Dialog, Founder Response International Services, Booz. Pennsylvania State University BS, Harvard University MBA
Ex-Microsoft, LucasArts, Electronic Arts, DreamWorks Interactive, Atomic Imaging, Day One Studios…
Co-Founder Medically Home, Ex-Flextronics, McKinsey. Northwestern University, University of Virginia MBA
Ex-Generation Health. Brown Medical School MD 1999
ational Academy of Sciences, American Academy of Arts and Sciences, National Academy of Medicine. Harvard College AB, Stanford University PhD
Ex-Q bio, Co-Founder ULink Technologies. Ghulam Ishaq Khan Institute of Engineering Sciences and Technology 2010, MIT ME 2012, PhD 2016
Ex- Philips, Hewlett-Packard, Agilent Technologies, Siemens Medical Solutions. Lehigh University BS 1984, University of Rochester MS 1989
The Bernstein Companies, ex-YPO, Massachusetts Institute of Technology MBA
Harvard Medical School Beth Israel Deaconess Medical Center, Harvard Medical School, 2010
University of Michigan, Harvard Medical School MD & PhD.
148 profiles with education records.
15 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
24,370 articles in the measured 12-month window.
Healthtech coverage tagged Boston · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 5,226 |
| 2021Q3 | 6,252 |
| 2021Q4 | 4,951 |
| 2022Q1 | 6,360 |
| 2022Q2 | 5,910 |
| 2022Q3 | 5,953 |
| 2022Q4 | 5,971 |
| 2023Q1 | 5,930 |
| 2023Q2 | 6,947 |
| 2023Q3 | 5,845 |
| 2023Q4 | 6,036 |
| 2024Q1 | 7,683 |
| 2024Q2 | 6,891 |
| 2024Q3 | 6,203 |
| 2024Q4 | 6,654 |
| 2025Q1 | 12,961 |
| 2025Q2 | 6,819 |
| 2025Q3 | 7,111 |
| 2025Q4 | 5,389 |
| 2026Q1 | 5,824 |
Article volume measures coverage, not market sales.
445 recorded company events across 56 companies; percentages use that event total.
Healthtech coverage tagged Boston · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| foreign policy analysis | 7,248 | 4,848 | 50% |
| multilateral diplomacy | 7,093 | 4,378 | 62% |
| national security strategy | 7,075 | 3,119 | 127% |
| bilateral trade | 5,915 | 4,221 | 40% |
| diplomatic engagements | 5,572 | 3,522 | 58% |
| vaccine candidates | 5,445 | 1,402 | 288% |
| vaccine trials | 4,931 | 1,374 | 259% |
| vaccination campaigns | 4,914 | 1,021 | 381% |
| countries | 4,204 | 1,897 | 122% |
| vaccine immunogenicity | 4,034 | 1,074 | 276% |
| olympic team selections | 1,407 | 2,836 | -50% |
| olympic trials | 1,103 | 2,360 | -53% |
| ceasefire violations | 903 | 1,703 | -47% |
| summer olympics athletics | 209 | 1,564 | -87% |
| electioneering tactics | 665 | 1,562 | -57% |
United States comparison coverage
territories, disputed islands, vaccine mandate compliance
42.5% critical · 22.3% positivepublic health funding, investment deal, inflation reports fx
46.9% critical · 41.2% positiveearnings report, quarterly results, quarterly financials
35.3% critical · 45.4% positiveHealthtech coverage tagged Boston. Topic labels describe recorded classifications and can include broad context.
8,843 papers in the recorded india scope.
Tone counts: 7,674 positive · 337 neutral · 832 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Realist synthesis: illustrating the method for implementation research
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0118.0% of this theme group
Researchers highlight difficulties in identifying effective compounds and translating findings into viable therapies.
Drug discovery (305) · Drug (169) · Pharmacogenomics (141) · Drug development (96)
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations
| Year | Share index |
|---|---|
| 2022 | 155.8 |
| 2023 | 160.7 |
| 2024 | 168.0 |
| 2025 | 209.7 |
Common problems researchers identify · 0218.0% of this theme group
Studies point to accessibility, equity, and evaluation gaps that limit telemedicine’s reach.
Telemedicine (687) · Telehealth (648) · Health care (347) · Nursing (98)
Ensuring full participation of people with disabilities in an era of telehealth
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 541.2 |
| 2023 | 553.5 |
| 2024 | 538.6 |
| 2025 | 840.0 |
Common problems researchers identify · 0313.6% of this theme group
Works expose fragmented administration, informatics, and public‑health coordination hindering service delivery.
Health administration (209) · Nursing research (154) · Health informatics (234) · Public health (215)
Is Europe putting theory into practice? A qualitative study of the level of self-management support in chronic care management approaches
Understanding integrated service delivery: a scoping review of models for noncommunicable disease and mental health interventions in low-and
| Year | Share index |
|---|---|
| 2022 | 22.0 |
| 2023 | 20.3 |
| 2024 | 26.9 |
| 2025 | 43.6 |
Common problems researchers identify · 0413.6% of this theme group
Authors note obstacles in subtyping diseases and delivering tailored treatments at scale.
Precision medicine (602) · Personalized medicine (282) · Cancer (105) · Disease (121)
The growing role of precision and personalized medicine for cancer treatment
Precision Medicine: Disease Subtyping and Tailored Treatment
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Common problems researchers identify · 0513.5% of this theme group
Papers discuss shortcomings in technology adoption, data standards, and system interoperability.
Digital health (431) · Health care (328) · Health informatics (149) · Informatics (73)
Technology and Universal Health Coverage: Examining the role of digital health
Digital Health and Health Systems of the Future
| Year | Share index |
|---|---|
| 2022 | 540.1 |
| 2023 | 553.1 |
| 2024 | 540.7 |
| 2025 | 849.1 |
Common problems researchers identify · 0613.1% of this theme group
Research flags unequal access and rapid rollout challenges during COVID‑19.
Pandemic (570) · Coronavirus disease 2019 (384) · 2019-20 coronavirus outbreak (108) · Telemedicine (386)
Telemedicine and health access inequalities during the COVID-19 pandemic
Examining telehealth use among primary care patients, providers, and clinics during the COVID-19 pandemic
| Year | Share index |
|---|---|
| 2022 | 661.4 |
| 2023 | 443.9 |
| 2024 | 330.0 |
| 2025 | 212.6 |
Common problems researchers identify · 0710.3% of this theme group
Studies emphasize the need for robust standards and usability testing for wearable and implantable devices.
Medical device (152) · Wearable computer (47) · Health care (152) · Food and drug administration (36)
The Need to Apply Medical Device Informatics in Developing Standards for Safe Interoperable Medical Systems
Medical Device Usability Analyses
| Year | Share index |
|---|---|
| 2022 | 564.5 |
| 2023 | 577.8 |
| 2024 | 564.0 |
| 2025 | 876.1 |
Cautions · 0124.5% of this theme group
Evidence warns of limited efficacy and cost‑effectiveness for home‑based telehealth in chronic disease management.
Telemedicine (394) · Telehealth (307) · Medical emergency (63) · Health care (134)
Home telehealth for chronic disease management: A systematic review and an analysis of economic evaluations
Transition to telehealth
| Year | Share index |
|---|---|
| 2022 | 215.3 |
| 2023 | 197.2 |
| 2024 | 209.5 |
| 2025 | 199.0 |
Cautions · 0215.8% of this theme group
Authors caution about implementation complexities and data governance when merging informatics with administration.
Health informatics (124) · Health administration (73) · Nursing research (49) · Health care (117)
A systematic approach to the planning, implementation, monitoring, and evaluation of integrated health services
INFORMATION SYSTEMS IN HEALTH MANAGEMENT: INNOVATIONS AND CHALLENGES IN THE DIGITAL ERA
| Year | Share index |
|---|---|
| 2022 | 22.0 |
| 2023 | 20.3 |
| 2024 | 26.9 |
| 2025 | 43.6 |
Cautions · 0315.4% of this theme group
Surveys reveal patient and clinician reservations about virtual care quality and privacy.
Pandemic (268) · Coronavirus disease 2019 (208) · Telemedicine (212) · Telehealth (177)
Patient Perception of Telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 Pandemic: A Single Center Survey-base
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Cautions · 0414.4% of this theme group
Reviews highlight inconsistent outcomes and limited evidence for genotype‑guided therapy.
Pharmacogenomics (86) · Drug discovery (91) · Drug (59) · Pharmacology (33)
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and <scp>Meta‐Analysis</scp> of Prospective, Controlled Clinic
Warfarin Pharmacogenomics in Diverse Populations
| Year | Share index |
|---|---|
| 2022 | 155.8 |
| 2023 | 160.7 |
| 2024 | 168.0 |
| 2025 | 209.7 |
Cautions · 0511.4% of this theme group
Analyses discuss variable effectiveness and potential harms of technology‑based psychological treatments.
Psychological intervention (118) · Digital health (104) · Mental health (62) · Intervention (56)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digitization and its Discontents: The Promise and Limitations of Digital Mental Health Interventions
| Year | Share index |
|---|---|
| 2022 | 784.7 |
| 2023 | 800.0 |
| 2024 | 802.5 |
| 2025 | 1143.3 |
Cautions · 0611.3% of this theme group
Critiques focus on insufficient trial data and reproducibility issues for targeted cancer therapies.
Precision medicine (127) · Personalized medicine (61) · Cancer (49) · Oncology (37)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Cautions · 077.1% of this theme group
Papers raise concerns about bias, transparency, and regulatory oversight in AI‑driven health solutions.
Applications of artificial intelligence (19) · Health care (53) · Precision medicine (36) · Personalized medicine (28)
Leveraging Artificial Intelligence for Predictive Healthcare: A Data-Driven Approach to Early Diagnosis and Personalized Treatment
Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine
| Year | Share index |
|---|---|
| 2022 | 543.5 |
| 2023 | 558.4 |
| 2024 | 545.5 |
| 2025 | 874.8 |
Opportunities · 0118.5% of this theme group
Research shows promising models for remote care that improve engagement and outcomes for older adults.
Telehealth (669) · Telemedicine (567) · Pandemic (136) · Coronavirus disease 2019 (120)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Using inpatient telehealth for family engagement: A mixed methods study of perceptions from patients, families, and care team providers
| Year | Share index |
|---|---|
| 2022 | 548.9 |
| 2023 | 380.0 |
| 2024 | 246.2 |
| 2025 | 194.7 |
Opportunities · 0216.2% of this theme group
Studies highlight in‑silico tools accelerating target identification and molecular optimization.
Drug discovery (597) · Computational biology (310) · Chemical space (104) · Drug (199)
Assessing molecular docking tools: understanding drug discovery and design
Landscape of <i>In Silico</i> Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery
| Year | Share index |
|---|---|
| 2022 | 182.1 |
| 2023 | 196.4 |
| 2024 | 225.2 |
| 2025 | 259.1 |
Opportunities · 0315.8% of this theme group
Works propose frameworks that combine informatics, public health, and clinical care for scalable interventions.
Digital health (225) · Health informatics (198) · Health care (254) · Public health (106)
IDEAS (Integrate, Design, Assess, and Share): A Framework and Toolkit of Strategies for the Development of More Effective Digital Interventi
Integrated Digital Mental Health Care: A Vision for Addressing Population Mental Health Needs
| Year | Share index |
|---|---|
| 2022 | 540.1 |
| 2023 | 553.1 |
| 2024 | 540.7 |
| 2025 | 849.1 |
Opportunities · 0415.7% of this theme group
Papers describe emerging drug candidates and innovative screening approaches with in‑vivo activity.
Drug discovery (269) · Drug (133) · Pharmacology (64) · In vivo (56)
Development and Characterization of Selective FAK Inhibitors and PROTACs with <i>In Vivo</i> Activity
A kinase to cytokine explorer to identify molecular regulators and potential therapeutic opportunities
| Year | Share index |
|---|---|
| 2022 | 512.3 |
| 2023 | 527.8 |
| 2024 | 495.0 |
| 2025 | 494.4 |
Opportunities · 0513.1% of this theme group
Research presents rapid mutational profiling and model selection to guide personalized cancer treatment.
Cancer (230) · Precision medicine (278) · Oncology (89) · Breast cancer (91)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Systems approach for congruence and selection of cancer models towards precision medicine
| Year | Share index |
|---|---|
| 2022 | 893.2 |
| 2023 | 1222.6 |
| 2024 | 953.9 |
| 2025 | 908.7 |
Opportunities · 0611.3% of this theme group
Studies explore phenome‑wide analyses and molecular subgrouping to improve disease prediction and therapy.
Precision medicine (299) · Personalized medicine (212) · Disease (137) · Health care (84)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification
| Year | Share index |
|---|---|
| 2022 | 1258.8 |
| 2023 | 1116.7 |
| 2024 | 1011.1 |
| 2025 | 1302.9 |
Opportunities · 079.4% of this theme group
Innovations in remote sensors and surgical robots enable real‑time patient monitoring and therapeutic support.
Wearable computer (90) · Remote patient monitoring (52) · Surgical robot (38) · Robot (36)
Development of a remote therapeutic monitoring platform: applications for movement disorders
IoT-enabled health monitoring system for real time patient care: Design and evaluation
| Year | Share index |
|---|---|
| 2022 | 32.7 |
| 2023 | 34.5 |
| 2024 | 35.7 |
| 2025 | 61.7 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Problem-identifying | 32.5% | 9.7% |
| Promising | 29.8% | 37.3% |
| Descriptive | 14.9% | 17.2% |
| Breakthrough | 11.9% | 26.5% |
| Cautionary | 7.3% | 4.2% |
| Comparative | 2.9% | 4.1% |
| Critical | 0.7% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 1,121 | 2.85% | 599 (53.4%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 72 | 0.18% | 36 (50.0%) | 0.17% |
| Bias & fairnessPrivacy Protection, Personalized Medicine, and Genetic Testing | 29 | 0.07% | 16 (55.2%) | 0.06% |
| Hardware, e-waste & supply chainToo many bits: tackling the waste epidemic in digital medicine | 4 | 0.01% | 1 (25.0%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 3 | 0.01% | 2 (66.7%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 2 | 0.01% | 2 (100.0%) | 0.01% |
| Labour & data workLabor markets for health supply chain management in Rwanda: a qualitative study of stakeholder perspectives | 2 | 0.01% | 2 (100.0%) | 0.01% |
| Carbon & emissions of computePotential reduction in healthcare carbon footprint by autonomous artificial intelligence | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 5 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗